Trial Profile
A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2022
Price :
$35
*
At a glance
- Drugs Aceclidine/tropicamide (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors LENZ Therapeutics; Presbyopia Therapies
- 18 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Sep 2015 New trial record